Payment overview · 2025
General Payments
$444.69
21 reported records · 11 companies
Healthcare provider profile · identity verified
Yusef Prince Williams, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DOTHAN, AL · NPI 1699904243
Verified facts
What the public records show
CMS Open Payments records show Yusef Prince Williams, M.D. received $444.69 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.10 | 43.6% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.11 | 10.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.33 | 8.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.52 | 7.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.86 | 5.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.24 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.25 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.94 | 3.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.95 | 3.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.44 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.95 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.69 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $162.64 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $160.98 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $48.11 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.81 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 165 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
165 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 486 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 133 |
| Losartan Potassium | Losartan Potassium | 454 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 84 |
| Lisinopril | Lisinopril | 248 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 73 |
| Metformin Hcl | Metformin Hcl | 240 | 73 |
| Meloxicam | Meloxicam | 238 | 73 |
| Simvastatin | Simvastatin | 231 | 56 |
| Gabapentin | Gabapentin | 204 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 58 |
| Clonazepam | Clonazepam | 179 | 31 |
| Omeprazole | Omeprazole | 174 | 55 |
| Mounjaro | Tirzepatide | 165 | 22 |
| Temazepam | Temazepam | 165 | 25 |
| Trazodone Hcl | Trazodone Hcl | 161 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 51 |
| Furosemide | Furosemide | 155 | 54 |
| Pregabalin | Pregabalin | 146 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 57 |
| Ezetimibe | Ezetimibe | 142 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 55 |
| Sertraline Hcl | Sertraline Hcl | 140 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 24 |
| Potassium Chloride | Potassium Chloride | 133 | 42 |
| Tramadol Hcl | Tramadol Hcl | 133 | 57 |
| Januvia | Sitagliptin Phosphate | 129 | 30 |
| Methocarbamol | Methocarbamol | 114 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 35 |
| Carvedilol | Carvedilol | 109 | 27 |
| Ozempic | Semaglutide | 109 | 24 |
| Allopurinol | Allopurinol | 104 | 27 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 101 | 11 |
| Montelukast Sodium | Montelukast Sodium | 96 | 29 |
| Celecoxib | Celecoxib | 89 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 40 |
| Jardiance | Empagliflozin | 85 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 28 |
| Eszopiclone | Eszopiclone | 82 | 22 |
| Nifedipine Er | Nifedipine | 81 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Azithromycin | Azithromycin | 71 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 20 |
| Donepezil Hcl | Donepezil Hcl | 63 | 20 |
| Mupirocin | Mupirocin | 62 | 33 |
| Spironolactone | Spironolactone | 62 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 22 |
| Glipizide | Glipizide | 61 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 53 |
| Clonidine Hcl | Clonidine Hcl | 59 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 23 |
| Metformin Hcl Er | Metformin Hcl | 59 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 21 |
| Eliquis | Apixaban | 57 | 17 |
| Glimepiride | Glimepiride | 55 | 17 |
| Atenolol | Atenolol | 54 | 15 |
| Colchicine | Colchicine | 54 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | 19 |
| Finasteride | Finasteride | 51 | 19 |
| Alprazolam | Alprazolam | 50 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 14 |
| Megestrol Acetate | Megestrol Acetate | 48 | 16 |
| Bumetanide | Bumetanide | 46 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 41 |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 13 |
| Glipizide Er | Glipizide | 43 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 39 |
| Fluconazole | Fluconazole | 42 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Farxiga | Dapagliflozin Propanediol | 41 | 15 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 15 |
| Ondansetron Odt | Ondansetron | 38 | 20 |
| Fenofibrate | Fenofibrate | 37 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 20 |
| Famotidine | Famotidine | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 18 |
| Prednisone | Prednisone | 35 | 19 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 17 |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Testosterone | Testosterone | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 13 |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Methimazole | Methimazole | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $444.69 · 21 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, FARXIGA, GVOKE HYPOPEN, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error